Brigatinib | List of Frontiers open access articles

Original Research

Published on 15 Feb 2024

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

in Health Economics

Wenjie Liu
Gengwei Huo
Peng Chen

Frontiers in Public Health

doi 10.3389/fpubh.2024.1213318

4,819 views

Case Report

Published on 11 Jul 2024

Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with ALK rearrangement

in Thoracic Oncology

Hayoung Seong
Soo Han Kim
Mi Hyun Kim
Jeong Su Cho
Ahrong Kim
Jung Seop Eom

Frontiers in Oncology

doi 10.3389/fonc.2024.1343238

2,064 views

Case Report

Published on 22 Jan 2025

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report

in Thoracic Oncology

Yang Zhang
Ke-jie Li
Can Wang
Chang-lin Zou
Meng Su

Frontiers in Oncology

doi 10.3389/fonc.2024.1503262

2,381 views

Original Research

Published on 18 Feb 2025

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells

in Experimental Pharmacology and Drug Discovery

Qi Yang
Dan Zhao
Linjie Ju
Peng Cao
Jifu Wei
Zhixian Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524277

3,455 views
4 citations

Systematic Review

Published on 03 Nov 2022

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

in Thoracic Oncology

Puyuan Xing
Xuezhi Hao
Xin Zhang
Junling Li

Frontiers in Oncology

doi 10.3389/fonc.2022.920709

6,503 views
9 citations

Case Report

Published on 21 Apr 2022

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib

in Thoracic Oncology

Yubo Wang
Rui Han
Mengxiao Zhu
Tingting He
Yong He

Frontiers in Oncology

doi 10.3389/fonc.2022.875313

4,010 views
10 citations

Case Report

Published on 20 Dec 2021

Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report

in Pharmacology of Anti-Cancer Drugs

Yadong Wang
Tiange Wang
Jianchao Xue
Ziqi Jia
Xinyu Liu
Bowen Li
Ji Li
Xiaoguang Li
Weiwei Wang
Zhongxing Bing

Frontiers in Pharmacology

doi 10.3389/fphar.2021.809467

4,231 views
8 citations

Case Report

Published on 03 Oct 2025

Patient-derived organoid facilitating personalized medicine in non-small cell lung cancer: two case reports

in Thoracic Oncology

Lili Qin
Shasha Wang
Liping Li
Haifeng Qin

Frontiers in Oncology

doi 10.3389/fonc.2025.1674897

2,125 views

Case Report

Published on 24 Apr 2025

Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4–ALK+ metastatic non-small cell lung adenocarcinoma

in Thoracic Oncology

Khyati Somayaji Dasika
Megan Melody
Jyoti D. Patel

Frontiers in Oncology

doi 10.3389/fonc.2025.1572425

2,455 views
1 citation

Case Report

Published on 18 Apr 2024

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

in Thoracic Oncology

Dan Li
Yue Zhu
Jincheng Song
Dafu Yang
Saiqiong Cui
Xin Liu
Le Wang
Jiangyan Zhang
Evenki Pan
Zhaoxia Dai

Frontiers in Oncology

doi 10.3389/fonc.2024.1339511

2,725 views
1 citation

Case Report

Published on 13 Nov 2024

Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer

in Thoracic Oncology

Waleed Kian
Belal Krayim
Betsy Giles
Nasim A. Elkiaan
Amjad Idris
Daniel Fink
Nir Peled
Laila C. Roisman

Frontiers in Oncology

doi 10.3389/fonc.2024.1286116

2,820 views
2 citations

Case Report

Published on 23 Sep 2025

Case Report: Treatment response of SQSTM1–ALK fusion lung adenocarcinoma to multiple ALK inhibitors

in Pharmacology of Anti-Cancer Drugs

Jincui Gu
Jing Zhang
Shaoli Li
Ziying Lin
Lixia Huang
Yanbin Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1608080

3,345 views

Original Research

Published on 21 Sep 2022

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

in Health Economics

Xia Luo
Zhen Zhou
Xiaohui Zeng
Liubao Peng
Qiao Liu

Frontiers in Public Health

doi 10.3389/fpubh.2022.985834

10,569 views
14 citations

Original Research

Published on 17 Mar 2023

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma

in Thoracic Oncology

Zhe-Rong Zheng
Hsiu-Ying Ku
Kun-Chieh Chen
Chun-Ju Chiang
Chih-Liang Wang
Chih-Yi Chen
Chun-Ming Tsai
Ming-Shyan Huang
Chong-Jen Yu
Jin-Shing Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1063695

3,369 views
5 citations

Original Research

Published on 23 Nov 2022

Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database

in Pharmacology of Anti-Cancer Drugs

Maria Antonietta Barbieri
Emanuela Elisa Sorbara
Giuseppe Cicala
Vincenza Santoro
Paola Maria Cutroneo
Tindara Franchina
Mariacarmela Santarpia
Nicola Silvestris
Edoardo Spina

Frontiers in Oncology

doi 10.3389/fonc.2022.1005626

5,200 views
21 citations

Original Research

Published on 09 May 2025

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data

in Pharmacology of Anti-Cancer Drugs

Vera Damuzzo
Lorenzo Gasperoni
Luna Del Bono
Andrea Ossato
Alessandro Inno
Andrea Messori

Frontiers in Oncology

doi 10.3389/fonc.2025.1566816

7,137 views
2 citations

Articles

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

Case report: Pathological complete response to neoadjuvant brigatinib in stage III non-small cell lung cancer with ALK rearrangement

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib

Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report

Patient-derived organoid facilitating personalized medicine in non-small cell lung cancer: two case reports

Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4–ALK+ metastatic non-small cell lung adenocarcinoma

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer

Case Report: Treatment response of SQSTM1–ALK fusion lung adenocarcinoma to multiple ALK inhibitors

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma

Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data